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Condensation 
 
Prediction of spontaneous preterm birth using cervicovaginal fluid quantitative fetal 
fibronectin in asymptomatic women with cervical surgery is valid. 
 
Short version of title 
 
Quantitative fetal fibronectin testing after cervical surgery  
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Abstract 
Background: Quantitative fetal fibronectin testing has demonstrated accuracy for 
prediction of spontaneous preterm birth in asymptomatic women with a prior 
history of preterm birth.  Predictive accuracy in women with previous cervical 
surgery (a potentially different risk mechanism) is not known.  
 
Objective: To compare the predictive accuracy of cervicovaginal fluid quantitative 
fetal fibronectin and cervical length testing in asymptomatic women with previous 
cervical surgery to that in women with one previous preterm birth.  
 
Study Design: A prospective blinded secondary analysis of a larger observational 
study of cervicovaginal fluid quantitative fetal fibronectin concentration in 
asymptomatic women measured with a Hologic 10q system (Hologic, Marlborough, 
MA). Prediction of spontaneous preterm birth (<30, 34 and 37 weeks) with 
cervicovaginal fluid quantitative fetal fibronectin concentration in primiparous 
women who had undergone at least one invasive cervical procedure (n=473) was 
compared with prediction in women who had previous spontaneous preterm birth, 
preterm prelabour rupture of membranes or late miscarriage (n=821).  Relationship 
with cervical length was explored. 
 
Results:  The rate of spontaneous preterm birth <34 weeks’ in the cervical surgery 
group was 3% compared with 9% in previous spontaneous preterm birth group. 
Receiver operating characteristic curves comparing quantitative fetal fibronectin for 
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prediction at all 3 gestational end-points were comparable between the cervical 
surgery and previous spontaneous preterm birth groups; (34 weeks: area under the 
curve 0.78 [0.64-0.93] vs. 0.71 [0.64-0.78] p=0.39). Prediction of spontaneous 
preterm birth using cervical length compared with quantitative fetal fibronectin for 
prediction of preterm birth before 34 weeks of gestation offered similar prediction; 
area under the curve 0.88 [0.79-0.96] vs. 0.77 [0.62-0.92] p=0.12 in the cervical 
surgery group; 0.77 [0.70-0.84] vs. 0.74 [0.67-0.81] p=0.32 in the previous 
spontaneous preterm birth group. 
 
Conclusion: Prediction of spontaneous preterm birth using cervicovaginal fluid 
quantitative fetal fibronectin in asymptomatic women with cervical surgery is valid, 
and has comparative accuracy to that in women with a history of spontaneous 
preterm birth.   
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Manuscript 
Quantitative fetal fibronectin to predict preterm birth in women with previous 
cervical surgery 
 
Introduction 
 
Preterm birth (birth before 37 weeks’ completed gestation) is responsible for over 1 
million neonatal deaths annually. Representing approximately 10% of all deliveries 
worldwide, rates are continuing to rise
1
.  Whilst prior history of spontaneous 
preterm birth (sPTB) is known to be a limited predictor of subsequent sPTB,
2
 
currently the two best available predictors for sPTB before 34 weeks of gestation are 
cervical length (CL) by transvaginal ultrasound scan (TVS) and cervicovaginal fluid 
(CVF) fetal fibronectin (FFN).
3
  
 
FFN is an adhesive glycoprotein normally found in the fetal membranes and decidua. 
As the gestational sac implants and attaches to the interior of the uterus in early 
pregnancy, presence of FFN in the CVF is regarded as ‘physiological’.
4
 A high 
concentration of CVF FFN after the 18 weeks’ of gestation may indicate mechanical 
or inflammatory medicated disruption of the attachment of the membranes to the 
decidua
5
. Detection of CVF FFN has demonstrated accuracy at predicting sPTB in 
asymptomatic high-risk women (women who have had a previous sPTB or late 
miscarriage), 
6
 and there is increasing evidence that the actual concentration of FFN 
(quantitative FFN, qFFN) measured in CVF allows more accurate discrimination of 
risk of sPTB. although its role in clinical practice is not yet established. 
7–9
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It is well established that women who have undergone invasive cervical surgery (e.g. 
laser loop excision, or cone biopsy for premalignant changes) are at more than 
double the risk of sPTB than the background population, although this may differ 
with procedure and depth of biopsy.
10
 Although used increasingly in clinical 
practice, the ability of qFFN to predict premature birth in women with previous 
cervical surgery, compared with women at high risk by virtue of their obstetric 
history, has never been described and routine FFN testing in asymptomatic women 
with prior cervical surgery is not recommended by NICE.
11
 It is possible that the 
aetiology underlying sPTB may be different in women with previous cervical surgery 
who have mechanically shortened cervices, compared with women with a previous 
sPTB, in whom decidual disruption results in activation of inflammatory pathways.
12
 
The predictive power of qFFN may be different in these two groups.  
 
We hypothesized that qFFN could be used to predict subsequent PTB in women with 
previous cervical surgery. The primary aim was to compare the predictive value of 
qFFN in a cohort of primiparous women with previous invasive cervical surgery, 
compared to women with prior sPTB. 
 
Materials and Methods 
 
This was a pre-defined prospective masked secondary analysis of a larger 
observational study of CVF qFFN concentration (ng/ml) in asymptomatic women 
using commercially available rapid bedside FFN testing (Hologic™).
9,13
 Samples 
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were taken between 22
+0
 -27
+6
 weeks’ gestation. The primary end-point of the study 
was sPTB (including premature prelabour rupture of membranes [PPROM]) with 
delivery before 34 weeks’, with secondary end points of delivery before 30 and 37 
weeks’ gestation. The study was conducted from October 2010 through July 2014 at 
5 teaching hospitals in the United Kingdom.  
 
The study was approved by the South East London Research Ethics Committee, and 
all local research ethics committees that were associated with participating centers. 
Informed written consent was obtained from all participants. Gestational age was 
confirmed by early obstetric ultrasound examination. According to hospital protocol 
and the licensing recommendations on qFFN testing, women with cervical dilation >3 
cm, frank bleeding, or rupture of membranes (on speculum examination) were 
excluded from the study because of interference with qFFN measurement (Figure 1). 
Samples that were blood stained, or from women who had undergone sexual 
intercourse or vaginal examination within the past 24 hours were excluded (due to 
known interference with qFFN measurement
14
), and the next eligible qFFN test was 
used if one was available within the gestational age limit of 22-27+6 weeks.  
 
Categorical TLIQ data (positive/negative) were provided to clinicians, but 
quantitative 10Q results remained masked (a random result code was generated by 
the analyzer) until after delivery. Thresholds of 10, 50, 200, and 500 ng/mL were 
predefined before analysis, based on the literature 
5,8
. A sterile speculum 
examination was performed, and a polyester swab was inserted for 10 seconds into 
the posterior fornix of the vagina to collect a sample of CVF. The swab was placed 
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into the test buffer solution and two tests were run concurrently. The first aliquot 
(200 µl) of this solution was analysed immediately with the conventional qualitative 
TLi Rapid FFN analyser (Hologic). Another aliquot was analysed with the quantitative 
Rapid 10Q FFN analyser (Hologic) by placing on a test cassette and inserting into the 
analyser; after 10 minutes a numerical result is displayed electronically. All clinicians 
were trained in the use of the FFN analyser. After FFN swabs were taken, at the 
same appointment, CL was measured (mm) using TVS performed by trained staff; 
the mean of three values was used in this analysis. All sonographers were formally 
trained by the institution’s governance requirements, which included formal 
assessment prior to accreditation. The mean value was taken to be consistent with 
our previous evidence.9 Cervical length measurements were taken and recorded 
prior to any FFN assay. 
 
From the cohort of asymptomatic high risk women who met the criteria for analysis 
(n= 1294), 2 groups of women were selected; primiparous women (no previous 
pregnancy lasting >14 weeks’ duration) with singleton pregnancies at 22-27
+6
 weeks 
of gestation who had undergone invasive cervical surgery (e.g. LLETZ, cone/loop 
biopsy) (n= 473) prior to their index pregnancy, and women with singleton 
pregnancies at 22-27
+6
 weeks of gestation, with prior sPTB <37 weeks’, premature 
rupture of membranes (PPROM) or miscarriage >14 weeks’ gestation, who had never 
undergone any cervical surgery (n= 821). Where multiple visits had occurred, the 
first eligible visit in the gestational age bracket was used. A formal power 
calculation was not performed as this was a planned subgroup analysis of a 
previously powered study.  We chose not to include multiparous women without 
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prior sPTB into the cervical surgery group to limit the number of variables 
affecting the risk of PTB. 
 
Descriptive characteristics were calculated for baseline demographics in both 
groups. Logistic regression and interaction tests were used to assess whether the 
meaning of the FFN test results varied according to the women’s risk 
group.  Calculations were carried out in Stata version 11.2 (StataCorp, College 
Station, Texas). The performance of qFFN as a predictor of sPTB was tested for 
different gestational age limits (prior to 34 weeks (primary outcome), 30 and 37 
weeks) and predictive statistics for sPTB were calculated and compared between the 
previous cervical surgery and previous PTB groups; ROC areas were calculated and 
compared,
15
 and sensitivity, specificity, predictive values, likelihood ratios and 
relative risk were assessed at pre-specified endpoints: 10, 50, 200, 500 ng/mL.  The 
utility of CL measurement following stratification by qFFN category was explored, as 
well as the utility of qFFN following stratification by the presence and absence of a 
short cervix (<25 mm). A composite score was developed by using logistic regression 
for the continuous variables of CL and the log of qFFN concentration to predict 
prematurity before 34 weeks. The composite score was compared with 2 continuous 
measurements of qFFN and CL using ROC curve analysis
15
. Iatrogenic PTB prior to the 
gestational age outcome under consideration were excluded from statistical analysis 
(Figure 1). 
   
Results 
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A total of 473 women with previous cervical surgery were eligible for analysis and 
comparison was made with 821 women with one previous sPTB. The mean 
gestational age of testing was 23
+3
 weeks (SD ±1.90). Demographics for study 
participants, and the nature of cervical surgery are illustrated in Figure 2. The 
proportion of women of African and Afro-Caribbean origin was lower in the cervical 
surgery group than previous sPTB.  
 
Concentrations of qFFN were obtained for all women with the use of the 10Q test. 
There were no adverse events related to the test. Overall, the rate of sPTB <34 
weeks’ after iatrogenic deliveries were excluded in the cervical surgery group was 
14/468 (3%) compared with 71/809 (9%) in the previous sPTB group. The number of 
women and proportion of preterm deliveries assigned to each of the pre-specified 
qFFN categories is shown in Table 2.  82% of women in the cervical surgery group 
and 61% in the sPTB group had CVF qFFN concentrations of <10ng/ml category.  
However, more than four times as many women with a previous sPTB had a qFFN 
concentration >200 ng/ml compared to those with prior cervical surgery (Table 2).   
 
The diagnostic accuracy of qFFN for predicting sPTB <30 weeks, <34 and <37 weeks’ 
gestation in each group using pre-specified thresholds is shown in Tables 3, 4 and 5. 
Using a qFFN concentration threshold of 10ng/ml gave a high negative predictive 
value for prediction of sPTB at all 3 gestational end-points in both groups. A qFFN 
concentration threshold of ≥200 ng/ml had high specificity for prediction of sPTB at 
all gestational end-points in both groups, although the optimal balance between 
sensitivity and specificity remains at 50ng/ml. 
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The relative risk (RR) of sPTB at each gestational endpoint for each qFFN 
concentration is shown in Table 6. In the cervical surgery group, the relative risk (RR) 
of sPTB <34 weeks for qFFN concentration threshold of 200g/ml was 21.8 (95% CI 
5.5-86.8), almost triple the relative risk at the same threshold in the previous sPTB 
group; RR 6.7 (3.6-12.6).  
 
Receiver operator characteristic (ROC) curves for prediction of sPTB < 30, < 34 and 
<37 weeks of gestation are shown in Figure 2. ROC curves for prediction at each 
gestational end-point were comparable between the cervical surgery and previous 
sPTB groups, and the differences between the groups were not statistically 
significant; (34 weeks: 0.78 [0.64-0.93] vs. 0.71 [0.64-0.78], p=0.39; 30 weeks: 0.82 
[0.64-0.99] vs. 0.73  [0.62-0.84], p=0.42; 37 weeks: 0.62 [0.50-0.74] vs. 0.65 (0.60-
0.70], p=0.69).   
 
Of the included cohort, 1,256 women had paired TVS CL measurements. Table 7 
illustrates the proportion of women who delivered prematurely, stratified according 
to CL measurement, qFFN concentration and risk factor (cervical surgery or previous 
sPTB). Women with iatrogenic PTB were excluded. Of these women, 32/463 (7%) in 
the cervical surgery group, and 104/793 (13%) in the previous sPTB group had a CL 
<25mm. 
 
Both FFN and CL were consistently strong and highly significant predictors of 
prematurity, as a test based on the combination, with little evidence that any test or 
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combination performed better than any other.  As expected, women with a short 
cervix (CL <25 mm) had a higher rate of sPTB before 34 weeks compared to women 
with CL >25mm; 7/32 (21.9%) vs. 7/431 (1.6%) in the cervical surgery group and 
33/104 (31.7%) vs. 38/689 (5.5%) in the previous sPTB group. Among those women 
with a short cervix, stratification according to qFFN concentration further 
discriminated risk of sPTB (Table 7). For example, 2/4 (50%) of women in the 
previous cervical surgery group with short cervix and a qFFN value >200 delivered 
<34 weeks compared with 3/23 (13%) in the same group with a qFFN <10 ng/ml (Risk 
difference: 37%, CI: 14% to 88%, P=0.079). Likewise 13/26 (50%) of women with 
previous sPTB and short cervix delivered spontaneously prior to 34 weeks, compared 
with 5/33 (15.2%) of women in the same group with the lowest qFFN concentrations 
(<10ng/ml) (Risk difference: 35%, CI: 12% to 58%, P=0.0039).   
 
Prediction of sPTB < 34 weeks using CL combined with qFFN offered superior 
prediction than using qFFN or CL alone, although this difference was only statistically 
significant in the previous cervical surgery group, and only for qFFN compared to the 
combination of CL and qFFN (P=0.021). For women with previous cervical surgery, 
prediction of sPTB using CL had ROC AUC of 0.87 (0.78-0.96) whereas qFFN in this 
cohort had a ROC AUC of 0.75 (0.759-0.91), p=0.11 for the difference; both tests 
combined had a ROC AUC of 0.89 (0.79-0.98) (p=0.02 compared to FFN alone, p= 
0.49 compared to CL alone). In the previous sPTB group, CL had a ROC AUC of 0.76 
(0.69-0.84), qFFN a ROC AUC of 0.72 (0.65-0.80), p=0.29 for the difference, and the 
combined tests had a ROC AUC of 0.78 (0.70-0.85) (p=0.08 compared to FFN alone, 
p=0.40 compared to CL alone). 0.6% of women in the previous cervical surgery group 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Vandermolen 
 
15 
 
and 2.4% of women in the previous PTB group underwent cervical cerclage during 
their pregnancy. It is therefore possible that the predictive ability of the tests have 
been underestimated. 
 
Comment 
 
These data demonstrate that CVF qFFN measurement using the rapid bedside 10Q 
analyser is a valuable and valid screening tool for assessing sPTB risk in 
asymptomatic primiparous women who have undergone prior cervical surgery, 
comparable to that in women with previous premature birth (in whom qFFN testing 
is well established).
8
 Based on these results, a primiparous woman who has 
undergone previous cervical surgery and found to have a raised qFFN concentration 
of any value ≥10ng/ml has a greater than double the risk of delivering spontaneously 
before 34 weeks’ gestation compared to a woman with a history of sPTB with the 
same qFFN test result, although absolute risks in this group remained lower.  It is 
difficult to compare the absolute risks of cervical surgery and prior history given the 
different demographic of the populations. In spite of this the predictive ability 
remained good and therefore is likely to be generalizable.   
 
Furthermore, the results confirm the increasingly recognised value of using 
quantitative, as opposed to qualitative fetal fibronectin; risk of sPTB is clearly related 
to the concentration of FFN in the CVF of women who have undergone previous 
cervical surgery.  There may be value in using alternative risk thresholds at <10 
ng/ml to define ‘low risk’ and >200 ng/ml to identify those women at higher risk, 
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rather than the traditional ‘positive/negative’ threshold of 50 ng/ml. Although 
50ng/ml is an appropriate single threshold, sensitivity and specificity are rarely 
equally weighted in clinical practice and quantification allows the clinician to 
tailor their decision-making. 
 
A clinical tool that can be used to differentiate so-called ‘high-risk’ women is highly 
desirable, due to the likely outcome being a term birth even amongst women with 
previous poor obstetric histories.  A test with a high sensitivity is desirable in these 
circumstances, when considering the balance of benefit and harm.  For women with 
a previous preterm birth, a threshold of 10ng/ml has high sensitivity and specificity 
for prediction of spontaneous preterm birth.  As such, a test with high sensitivity 
allows clinicians to reassure high-risk women with low qFFN concentration that they 
are likely to have a term birth. At all thresholds, sensitivity, specificity, positive and 
negative predictive values in both the cervical surgery group and previous sPTB are 
comparable; thus this test can be used with comparable accuracy in both 
asymptomatic high risk groups.  
 
This is the largest study of qFFN to date in high-risk women with data obtained from 
a prospectively collected masked dataset. In terms of generalizability of results, the 
study population and sPTB rate was comparable to previously published high-risk 
studies. The study population was of varied ethnic origin and thus the test can be 
considered transferable to a broad high-risk population. The difference in 
ethnicities between the comparison groups may reflect the aetiology of the 
diseases being investigated, but there is no evidence to suggest the predictive 
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ability of the test is related to ethnicity. Although this generalizability is limited 
to nulliparous women, the mechanism in multiparous women is likely to be 
similar. 
 
A limitation of the study design was that women involved with a history of 
pregnancy loss or early preterm birth were routinely offered cerclage if a short cervix 
was detected, a management compliant with UK Royal College of Obstetrician and 
Gynaecologist guidelines (progesterone is not routinely prescribed). The use of 
cerclage may have influenced outcome (a likely 50% reduction in risk of sPTB <34 
weeks’ in these circumstances). A proportion of women in both groups underwent 
cervical cerclage during their pregnancy. As so few women received intervention 
(0.6% of women in the previous cervical surgery group and 2.4% of women in the 
previous PTB group) in both groups, this is unlikely to have had a major effect on 
the comparison between them. It is therefore possible that the predictive ability of 
the tests have been underestimated, as the cerclage may make a positive test a 
false positive result, and therefore the sensitivity could be even higher.
16
  
 
It is well known that women with previous cervical surgery are at increased risk of 
preterm birth (RR 1.25-2.61 depending on the height of conization)
17–19
.  There are 
several proposed mechanisms to explain their increased risk; structurally, the 
removal of cervical tissue may produce a mechanically weakened, shortened cervix 
which reduces its functioning during pregnancy, an effect that increases with 
increasing proportion of tissue removed.
20
 It has also been suggested that previous 
cervical conisation leads to an impaired inflammatory response during pregnancy 
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due to the loss of cervical glands, increasing the susceptibility to infection as well as 
altering the cervical flora to increase the risk of preterm premature rupture of the 
membranes (PPROM).
12,19
 In contrast, infection and inflammation are thought to 
play a major etiological role in sPTB without a history of cervical surgery, particularly 
at early gestations.
21
  
 
A recent paper by the RCOG Science Advisory Committee has stressed the need to 
determine antenatal interventions that could reduce the risk of sPTB for women who 
have had previous cervical surgery.  Prediction of PTB using qFFN allows a clinician to 
reassure those women at low risk and direct them back to routine antenatal care, 
whilst identifying those at the highest risk, allowing for targeted interventions. These 
include providing antenatal corticosteroids and in utero transfer, as well as 
potentially guiding prophylactic intervention such as cervical cerclage or vaginal 
progesterone, but further trials are needed to confirm their efficacy in these groups.    
 
CVF qFFN testing is a useful adjunct to CL measurement to accurately discriminate 
those women with a short cervix who were destined to deliver early; in the cervical 
surgery group, 3/23 (13%) of women who had a CL of <25mm and qFFN <10 ng/mL 
delivered spontaneously prior to 34 weeks’ gestation, compared with 2/4 (50%) of 
those with a qFFN >200ng/mL. However, in contrast to TVS measurement of CL, 
qFFN can be performed with little training and depending on service provision, it 
may prove to be as useful and cheaper used as a stand-alone test.   In the absence of 
CL measurement availability, a qFFN value of <10 ng/mL in a woman who is 
otherwise high risk having had previous cervical surgery will be immensely 
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reassuring (<1.5% risk of sPTB <34 weeks). Currently NICE recommends 
consideration of prophylactic cervical cerclage for women with CL< 25 mm at 16-24 
weeks gestation who have either previous sPTB or a history of cervical trauma.
11
 
Given that many women with a short cervix do not deliver early, qFFN may be able 
to discriminate those women who may benefit from cerclage, and avoid over-
treatment. This can be relied on as the risk of sPTB is lower than background risk 
if qFFN measurement is low and cervical length is long. 
 
In the overall cohort study
9
, (which included both women with cervical surgery and 
women with previous pre-term birth, as well as uterine abnormalities) from which 
these women were selected, we demonstrated that the relative risk of sPTB 
increased as concentrations of qFFN increased and that thresholds of <10ng/ml and 
>200 ng/ml were particularly clinically relevant.  The current study confirms that 
these observations are valid in women with previous cervical surgery alone. 
 
Currently, women with previous cervical surgery are not routinely offered antenatal 
CVF screening for risk of PTB.
11
 As this group has higher PTB rates than background 
rates, we believe screening is justified in this population.  The implementation of 
qFFN, a clinically useful, low-risk, test has the potential to discriminate between 
women with a history of cervical surgery who no longer need intensive surveillance 
(the majority) from those whose risk is elevated, particularly if combined with 
cervical length surveillance and who may ultimately require intervention.  The 
challenge remains to identify the most appropriate prophylactic intervention in 
those considered at high risk.   
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Table 1: Demographic and obstetric characteristics of high-risk asymptomatic 
women tested   for cervicovaginal fluid fetal fibronectin concentration from 22
+0
 – 
27
+6
 weeks’ gestation 
Characteristic Cervical surgery 
(n= 473) 
Previous sPTB 
(n=821) 
Age (years, mean ± SD)
 
33 ±4.2 32 ±5.5 
Body mass index (kg/m
2
, mean ± SD)
 
23 ±3.5 26.8 ±5.6 
Ethnicity, n (%):   
     European 411 (87) 321 (39) 
     African & Afro-Caribbean 9 (2) 332 (41) 
     Other 53 (11) 168 (20) 
Smoking history, n (%):   
     Current 10 (2) 50 (6) 
     Ex-smoker 127 (27) 101 (12) 
     Never 336 (71) 670 (82) 
Obstetric history:   
     Any previous pregnancy, n (%) 155 (32.8) 821 (100) 
     Gestation of previous pregnancy 
(weeks, mean ± SD) 
8.1 (2.3) 32.3 (7.6) 
     Outcome of previous birth   
          sPTB, n (%) - 566 (69) 
          PPROM, n (%) - 290 (35) 
          Late miscarriage (16-23 weeks gest), 
n (%) 
- 315 (38) 
Cervical surgery, n (%):   
     Cone 90 (19) - 
     LLETZ 370 (78.2) - 
     Laser 51 (10.7) - 
     Trachelotomy 2 (0.4) - 
     Other 34 (7.1) - 
     Combination 19 (4)  
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Table 2:  Spontaneous pre-term birth in asymptomatic high risk women according to 
quantitative fetal fibronectin (qFFN) categories, for both the cervical surgery group 
(non-shaded) and previous spontaneous preterm birth (sPTB) group (shaded) 
 
qFFN category 
(ng/ml) 
 
Test 
 
Total 
N (%) 
Spontaneous Preterm Birth  
   < 30 weeks  
N (%) 
<34 weeks 
N (%)  
<37 weeks  
N (%) 
Less than 10 Cervical Surgery 389 (82.2) 3 (0.8) 6 (1.5) 21 (5.4) 
Previous sPTB 504 (61.4) 9 (1.8) 24 (4.8) 68 (13.5) 
10-49 Cervical Surgery 43 (9.1) 0  1 (2.3) 4 (9.3) 
Previous sPTB 165 (20.1) 5 (3.0) 18 (10.9) 36 (21.8) 
50-199 Cervical Surgery 21 (4.4) 1 (4.8) 4 (19.0) 6 (28.6) 
Previous sPTB 82 (10.0) 4 (4.9) 14 (17.0) 23 (28.0) 
200-499 Cervical Surgery 6 (1.3) 1 (16.7) 2 (33.3) 3 (50) 
Previous sPTB 34 (4.1) 8 (23.5) 11 (32.4) 15 (44.1) 
500 or greater Cervical Surgery 4 (0.8) 1 (25) 1 (25) 1 (25) 
 Previous sPTB 8 (1.0) 3 (37.5) 4 (50.0) 4 (50.0) 
Total * Cervical Surgery 473 (100) 6 (1.3) 14 (3.0) 35 (7.4) 
Previous sPTB 821 (100) 29 (3.5) 71 (8.6) 146 (17.8) 
* Women with iatrogenic deliveries before the gestation of analysis were excluded 
(cervical surgery group; n=1 less than 30 weeks of gestation, n=4 less than 34 weeks 
of gestation, n=5 less than 37 weeks of gestation. Previous sPTB group; n=8 less than 
30 weeks of gestation, n=4 less than 34 weeks of gestation, n=16 less than 37 weeks 
of gestation). 
† All comparisons for each gestational endpoint are statistically significant (P<.01) 
except 10–49 ng/mL compared with 50–199 ng/mL and 200–499 compared with 500 
or greater (P>.1 for all gestational endpoints). 
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Table 3: Prediction of spontaneous preterm birth at <30 weeks’ gestation according 
to fetal fibronectin concentration for both the cervical surgery group (non-shaded) 
and previous sPTB (shaded) 
  Fetal fibronectin threshold (ng/ml) 
Predictive 
variable 
(95% CI) 
Test ≥10 
 
≥50 ≥200 ≥500 
Sensitivity 
(%) 
Cervical 
Surgery 
50  
(11.8-88.2) 
50  
(11.8-88.2) 
33.3  
(4.3-77.7) 
16.7  
(0.4-64.1) 
Previous 
sPTB 
69.0  
(49.2-84.7) 
51.7  
(32.5-70.6) 
37.9  
(20.7-57.7) 
10.3  
(2.2-27.4) 
Specificity 
(%) 
Cervical 
Surgery 
84.1  
(80.5-87.3) 
94.0  
(91.4-96.0) 
98.3  
(96.6-99.3) 
99.4  
(98.1-99.9) 
Previous 
sPTB 
64.7  
(61.2-68.0) 
85.7  
(83.1-88.1) 
95.8  
(94.1-97.1) 
99.4  
(98.5-99.8) 
PPV (%) 
 
Cervical 
Surgery 
3.9  
(0.8-11.0) 
9.7  
(2.0-25.8) 
20.0  
(2.5-55.6) 
25.0  
(0.6-80.6) 
Previous 
sPTB 
6.7  
(4.2-10.2) 
11.8  
(6.8-18.7) 
25.0  
(13.2-40.3) 
37.5  
(8.5-75.5) 
NPV (%) 
 
Cervical 
Surgery 
99.2  
(97.8-99.8) 
99.3  
(98.0-99.9) 
99.1  
(97.8-99.8) 
98.9  
(97.5-99.7) 
Previous 
sPTB 
98.3  
(96.7-99.2) 
98.0  
(96.6-98.9) 
97.7  
(96.3-98.6) 
96.8  
(95.3-97.9) 
LR + 
 
Cervical 
Surgery 
3.15  
(1.4-7.2) 
8.32  
(3.5-20.0) 
19.42  
(5.2-73.0) 
25.89  
(3.1-214.6) 
Previous 
sPTB 
1.95  
(1.5-2.5) 
3.62  
(2.5-5.4) 
9.01  
(5.1-16.0) 
16.22  
(4.1-64.6) 
LR – 
 
Cervical 
Surgery 
0.59  
(0.3-1.3) 
0.53  
(0.2-1.2) 
0.68  
(0.4-1.2) 
0.84  
(0.6-1.2) 
Previous 
sPTB 
0.48  
(0.3-0.8) 
0.56  
(0.4-0.8) 
0.65  
(0.5-0.9) 
0.90  
(0.8-1.0) 
ROC area 
 
Cervical 
Surgery 
0.82 (0.64-0.99) 
Previous 
sPTB 
0.73 (0.62-0.84) 
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Table 4: Prediction of spontaneous preterm birth at <34 weeks’ gestation according 
to fetal fibronectin concentration for both the cervical surgery group (non-shaded) 
and previous sPTB (shaded) 
 
 
 
 
  Fetal fibronectin threshold (ng/ml) 
Predictive 
variable 
(95% CI) 
Test ≥10 
 
≥50 ≥200 ≥500 
Sensitivity 
(%) 
Cervical 
Surgery 
57.1 
(28.9-82.3) 
50.0 
(23.0-77.0) 
21.4  
(4.7-50.8) 
7.1 
(0.2-33.9) 
Previous 
sPTB 
66.2 
(54.0-77.0) 
40.8 
(29.3-53.2) 
21.1 
(12.3-32.4) 
5.6 
(1.6-13.8) 
Specificity 
(%) 
Cervical 
Surgery 
85.0 
(81.4-88.2) 
94.7 
(92.2-96.6) 
98.5 
(96.8-99.4) 
99.3 
(98.1-99.9) 
Previous 
sPTB 
66.4 
(62.9-69.8) 
86.9 
(84.2-89.2) 
96.2 
(94.6-97.5) 
99.5 
(98.6-99.9) 
PPV (%) 
 
Cervical 
Surgery 
10.5 
(4.7-19.7) 
22.6 
(9.6-41.1) 
30.0  
(6.7-65.2) 
25.0 
(0.6-80.6) 
Previous 
sPTB 
15.9 
(11.9-20.6) 
23.0 
(16.0-31.4) 
34.9 
(21.0-50.9) 
50.0 
(15.7-84.3) 
NPV (%) 
 
Cervical 
Surgery 
98.5 
(96.7-99.4) 
98.4 
(96.7-99.4) 
97.6 
(95.7-98.8) 
97.2  
(95.3-98.5) 
Previous 
sPTB 
95.3 
(93.1-97.0) 
93.9 
(91.8-95.5) 
92.7 
(90.6-94.4) 
91.6 
(89.5-93.5) 
LR + 
 
Cervical 
Surgery 
3.8 
(2.3-6.3) 
9.5 
(4.9-18.2) 
13.9 
(4.0-48.2) 
10.8 
(1.2-97.5) 
Previous 
sPTB 
2.0 
(1.6-2.4) 
3.1 
(2.2-4.6) 
5.6 
(3.1-9.9) 
10.4 
(2.7-40.7) 
LR – 
 
Cervical 
Surgery 
0.5 
(0.3-0.9) 
0.5 
(0.3-0.9) 
0.8 
(0.6-1.1) 
0.9 
(0.8-1.1) 
Previous 
sPTB 
0.51 
(0.4-0.7) 
0.7 
(0.6-0.8) 
0.8 
(0.7-0.9) 
1.0 
(0.9-1.0) 
ROC area 
 
Cervical 
Surgery 
0.78 (0.64-0.93) 
Previous 
sPTB 
0.71 (0.64-0.78) 
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Table 5: Prediction of spontaneous preterm birth at <37 weeks’ gestation according 
to fetal fibronectin concentration for both the cervical surgery group (non-shaded) 
and previous sPTB (shaded) 
 
 
 
 
  Fetal fibronectin threshold (ng/ml) 
Predictive 
variable 
(95% CI) 
Test ≥10 
 
≥50 ≥200 ≥500 
Sensitivity 
(%) 
Cervical 
Surgery 
40.0 
(23.9-57.9) 
28.6 
(14.6-46.3) 
11.4 
(3.2-26.7) 
2.9 
(0.1-14.9) 
Previous 
sPTB 
53.4 
(45.0-61.7) 
28.8 
(21.6-36.8) 
13.0 
(8.0-19.6) 
2.7 
(0.8-6.9) 
Specificity 
(%) 
Cervical 
Surgery 
86.0 
(82.3-89.1) 
95.1 
(92.6-96.9) 
98.6 
(97.0-99.5) 
99.3 
(98.0-99.9) 
Previous 
sPTB 
67.4 
(63.6-71.0) 
87.3 
(84.5-89.8) 
96.4 
(94.7-97.7) 
99.4 
(98.4-99.8) 
PPV (%) 
 
Cervical 
Surgery 
18.9 
(10.7-29.7) 
32.3 
(16.7-51.4) 
40.0 
(12.2-73.8) 
25.0 
(0.6-80.6) 
Previous 
sPTB 
27.0 
(22.0-32.5) 
33.9 
(25.6-42.9) 
45.2 
(29.8-61.3) 
50.0 
(15.7-84.3) 
NPV (%) 
 
Cervical 
Surgery 
94.6 
(91.9-96.6) 
94.2 
(91.6-96.2) 
93.2 
(90.4-95.3) 
92.6 
(89.8-94.8) 
Previous 
sPTB 
86.5 
(83.2-89.4) 
84.5 
(81.5-87.1) 
83.1 
(80.2-85.7) 
81.9 
(79.0-84.5) 
LR + 
 
Cervical 
Surgery 
2.9 
(1.8-4.6) 
5.8 
(3.0-11.4) 
8.2 
(2.4-27.5) 
4.1 
(0.4-38.2) 
Previous 
sPTB 
1.6 
(1.4-2.0) 
2.3 
(1.6-3.1) 
3.7 
(2.1-6.5) 
4.4 
(1.1-17.5) 
LR – 
 
Cervical 
Surgery 
0.7 
(0.5-0.9) 
0.8 
(0.6-0.9) 
0.9 
(0.8-1.0) 
1.0 
(0.9-1.0) 
Previous 
sPTB 
0.7 
(0.6-0.8) 
0.82 
(0.73-0.91) 
0.9 
(0.9-1.0) 
1.0 
(1.0-1.0) 
ROC area 
 
Cervical 
Surgery 
0.62 (0.50-0.74) 
Previous 
sPTB 
0.65 (0.60-0.70) 
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Table 6: Relative risk of sPTB at < 30, <34 and <37 weeks’ gestation according to 
quantitative fetal fibronectin concentration for both the cervical surgery group (non-
shaded) and previous spontaneous preterm birth group (shaded) 
 
  Spontaneous Preterm Birth 
qFFN 
category 
(ng/ml) 
Test <30 weeks <34 weeks <37 weeks 
  Relative Risk (95% CI) 
Less 
than 10 
 
Cervical surgery 1 1 1 
 Previous sPTB 1 1 1 
10-49 Cervical Surgery 1 1.5 (0.2-11.8) 1.7 (0.62-4.8) 
 Previous sPTB 1.7 (0.6-5.0) 2.3 (1.3-4.1) 1.7 (1.7-3.5) 
50-199 Cervical Surgery 6.3 (0.7-57.7) 12.4 (3.8-40.8) 5.3 (2.4-11.7) 
 Previous sPTB 2.8 (0.9-8.8) 3.6 (2.0-6.7) 2.4 (1.7-3.5) 
200-500 Cervical Surgery 21.9 (2.6-181.9) 21.8 (5.5-86.8) 3.3 (2.1-5.1) 
 Previous sPTB 12.7 (5.2-31.0) 6.7 (3.6-12.6) 3.7 (2.5-5.6) 
>500 Cervical Surgery 32.9 (4.3-252.5) 16.3 (2.5-106.4) 3.7 (1.8-7.7) 
 Previous sPTB 21.5 (7.1-64.9) 10.7 (4.8-23.7) 3.9 (2.0-7.7) 
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Table 7: Proportion of women who delivered prematurely when analysed according 
to cervical length (CL) measurement (above and below 15 mm) and quantitative fetal 
fibronectin (qFFN) category.   
 
    Spontaneous Preterm Birth 
Cervical 
length 
qFFN 
category 
(ng/ml) 
Test N* <30 
weeks 
<34 
weeks 
<37 
weeks 
    N(%)                 N(%)                 N(%) 
≥25 mm <10 Cervical 
Surgery 
366 2 (0.4) 3 (0.6) 13 (2.7) 
  Previous sPTB 471 6 (0.7) 19 (2.3) 60 (7.3) 
 10-199 Cervical 
Surgery 
59 0 (0.0) 3 (0.6) 8 (1.7) 
  Previous sPTB 202 3 (0.4) 17 (2.1) 35 (4.2) 
 ≥200 Cervical 
Surgery 
6 1 (0.2) 1 (0.2) 2 (0.4) 
  Previous sPTB 16 1 (0.1) 2 (0.2) 4 (0.5) 
 Total* Cervical 
Surgery 
431 3 (0.6) 7 (1.4) 23 (4.9) 
  Previous sPTB 689 10 (1.2) 38 (4.6) 99 (12.1) 
<25 mm <10 Cervical 
Surgery 
23 1 (0.2) 3 (0.6) 8 (1.7) 
  Previous sPTB 33 3 (0.4) 5 (0.6) 8 (1.0) 
 10-199 Cervical 
Surgery 
5 1 (0.2) 2 (0.4) 2 (0.4) 
  Previous sPTB 45 6 (0.7) 15 (1.8) 24 (2.9) 
 ≥200 Cervical 
Surgery 
4 1 (0.2) 2 (0.4) 2 (4.2) 
  Previous sPTB 26 10 (1.2) 13 (1.6) 15 (1.8) 
 Total* Cervical 
Surgery 
32 3 (0.6) 7 (1.4) 12 (2.5) 
  Previous sPTB 104 19 (2.3) 33 (4.0) 47 (5.7) 
 
* Women with iatrogenic deliveries before the gestation of analysis were excluded 
(cervical surgery group; n=1 less than 30 weeks of gestation, n=4 less than 34 weeks 
of gestation, n=5 less than 37 weeks of gestation. Previous sPTB group; n=8 less than 
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30 weeks of gestation, n=4 less than 34 weeks of gestation, n=16 less than 37 weeks 
of gestation). 
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Figure Legend: 
Figure 1. Standards for the reporting of diagnostic accuracy studies (STARD) flow 
diagram illustrates the number of participants who were involved in study and those 
who were excluded according to defined exclusion criteria.  
Figure 2. ROC curves for prediction of sPTB before 30, 34 and 37 weeks gestation 
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